Figure 3.

Evaluation of doxorubicin effect on earlier-acquired protective titers and secondary B-cell responses against measles. (A) Serum anti-measles IgG titers were determined with Enzygnost^® ELISA (Siemens, P=0.002 between day 86 and 121 for all animals jointly). The relative Ab titer increase did not differ between the groups (P=1.0). (B) BMPCs were assessed with flow cytometry and defined as viable CD19⁺, CD20^+/−, CD38^hi, CD138⁺ single cells, shown as percentage of CD19⁺ BM cells. Proportions of (C) total IgG⁺ and (D) measles-specific IgG⁺ BMPC determined by ELISPOT. Representative wells from day 73 are shown. No statistically significant changes were noticed over time.